Pengcheng Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pengcheng Yu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Charles E. Rupprecht
College of Forestry, Wildlife and Environment, Auburn University, Auburn, AL 36849, USA
2 shared publications - Eric Tsao
Synermore Biologics (Suzhou) Co., Ltd., Suzhou, China
2 shared publications - Jiagui Qu
Synermore Biologics (Suzhou) Co., Ltd., Suzhou 215000, China
2 shared publications - Qun Lin
Synermore Biologics (Suzhou) Co., Ltd., Suzhou 215000, China
2 shared publications - Shiyun He
Synermore Biologics (Suzhou) Co., Ltd., Suzhou 215000, China
2 shared publications - Wu Yang Zhu
NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
2 shared publications
Latest Publications
- Open Access
SYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background/Objectives: Lyssaviruses pose a persistent global public health threat, underscoring the need for broad-spectrum neutralizing antibodies to improve rabies post-exposure prophylaxis (PEP). The humanized monoclonal antibody cocktail SYN023 is approved for PEP in China and under active global regulatory review. This study aimed to validate pseudovirus-based neutralization assays, verify SYN023 epitope prediction accuracy, and systematically characterize its pan-lyssavirus neutralizing activity. Methods: Assay validation was performed by directly comparing neutralization titers obtained with authentic rabies virus (RABV) and pseudotyped virus. Epitope analysis was performed, followed by in vivo evaluation in a canine PEP challenge model. The pseudovirus-based neutralization assay was used to assess SYN023 broad-spectrum activity across diverse lyssaviruses. Results: Neutralization titers from authentic and pseudotyped viruses showed high concordance (R2 = 0.8341, p < 0.0001), supporting the pseudovirus system as a reliable surrogate assay. Epitope analysis confirmed that SYN023’s epitope is fully conserved in the highly virulent New York City (NYC) RABV strain. In canine PEP challenge studies using the NYC strain, SYN023 conferred strong protection at 0.1–0.5 mg/kg. SYN023 exhibited potent neutralizing activity against phylogenetically diverse non-rabies lyssaviruses, including Mokola virus (MOKV; EC50 = 14.74 µg/mL), whereas three clinically validated reference antibodies failed to neutralize MOKV even at concentrations up to 1000 µg/mL. Conclusions: This study demonstrates that the pseudovirus-based neutralization assay is a reliable surrogate assay. It also confirms the functional accuracy of the epitope mapping strategy and demonstrates the broad neutralization spectrum of SYN023 against a diverse panel of lyssaviruses.
Open AccessSYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background/Objectives: Lyssaviruses pose a persistent global public health threat, underscoring the need for broad-spectrum neutralizing antibodies to improve rabies post-exposure prophylaxis (PEP). The humanized monoclonal antibody cocktail SYN023 is approved for PEP in China and under active global regulatory review. This study aimed to validate pseudovirus-based neutralization assays, verify SYN023 epitope prediction accuracy, and systematically characterize its pan-lyssavirus neutralizing activity. Methods: Assay validation was performed by directly comparing neutralization titers obtained with authentic rabies virus (RABV) and pseudotyped virus. Epitope analysis was performed, followed by in vivo evaluation in a canine PEP challenge model. The pseudovirus-based neutralization assay was used to assess SYN023 broad-spectrum activity across diverse lyssaviruses. Results: Neutralization titers from authentic and pseudotyped viruses showed high concordance (R2 = 0.8341, p < 0.0001), supporting the pseudovirus system as a reliable surrogate assay. Epitope analysis confirmed that SYN023’s epitope is fully conserved in the highly virulent New York City (NYC) RABV strain. In canine PEP challenge studies using the NYC strain, SYN023 conferred strong protection at 0.1–0.5 mg/kg. SYN023 exhibited potent neutralizing activity against phylogenetically diverse non-rabies lyssaviruses, including Mokola virus (MOKV; EC50 = 14.74 µg/mL), whereas three clinically validated reference antibodies failed to neutralize MOKV even at concentrations up to 1000 µg/mL. Conclusions: This study demonstrates that the pseudovirus-based neutralization assay is a reliable surrogate assay. It also confirms the functional accuracy of the epitope mapping strategy and demonstrates the broad neutralization spectrum of SYN023 against a diverse panel of lyssaviruses.
- Open Access
- 3 September 2026
- Published by MDPI AG in Preprints.org
SYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background: Lyssaviruses remain a global public health threat, requiring broad-spectrum, high-potency neutralizing antibodies as part of recommended human rabies post-exposure prophylaxis (PEP). A humanized monoclonal antibody cocktail, SYN023, is approved for PEP in China and is under global regulatory review. Its epitope mapping data are promising. However, the neutralization breadth across diverse lyssaviruses and the reliability of pseudovirus-based neutralization assays still require comprehensive validation to support worldwide regulatory approval and clinical use. Methods: First, the correlation between authentic lyssaviruses virus and pseudotyped viruses neutralization was established experimentally to verify the reliability of the pseudovirus-based neutralization assay. Second, epitope mapping was performed using a highly virulent rabies virus (RABV) variant (New York City strain: NYC) provided by the U.S. Department of Agriculture, followed by in vivo PEP efficacy studies in a standardized canine model to functionally validate the mapped epitopes. Third, the neutralizing activity of SYN023 was evaluated against a phylogenetically diverse panel of non-RABV lyssaviruses and directly benchmarked against clinically validated comparator monoclonal antibodies, thereby providing robust, quantitative empirical evidence supporting its broad-spectrum neutralization capability. Results: A strong positive correlation was observed between neutralization titers elicited by authentic lyssaviruses and pseudotyped viruses (Pearson R2 = 0.83, P < 0.0001), validating the pseudovirus-based assay as a robust surrogate for authentic virus neutralization. Specifically, SYN023 recognized and potently neutralized the epitope mapped on the prototypic NYC RABV strain. The in vivo PEP studies conducted in a standardized canine challenge model, using the NYC strain as the challenge virus, demonstrated high protective efficacy at SYN023 doses ranging from 0.1 to 0.5 mg/kg. Furthermore, SYN023 exhibited broad, potent, and reproducible neutralizing activity against a phylogenetically diverse panel of non-RABV lyssaviruses, including European bat lyssavirus 1 (EBLV1), European bat lyssavirus 2 (EBLV2), Australian bat lyssavirus (ABLV), Bokeloh bat lyssavirus (BBLV), Taiwan bat lyssavirus 1 (TWBLV1), Taiwan bat lyssavirus 2 (TWBLV2), Kotalahti bat lyssavirus (KBLV), Divača bat lyssavirus (DBLV), Gannoruwa bat lyssavirus (GBLV), Duvenhage virus (DUVV), Khujand virus (KHUV), Aravan virus (ARAV), Mokola virus (MOKV), Lagos bat virus (LBV) and Shimoni bat virus (SHIBV). Notably, SYN023 achieved robust neutralization of MOKV (EC50 = 14.74 µg/mL), whereas clinically referenced monoclonal antibodies—Rabishield, Ormutivimab and GR1801—exhibited no detectable neutralizing activity against MOKV even at concentrations up to 1,000 µg/mL. This pan-lyssavirus neutralizing capacity was attributable mechanistically to SYN023’s targeting of a highly conserved conformational epitope within the viral glycoprotein, which is structurally preserved across all major lyssavirus phylogroups. Conclusion: This study demonstrated that the pseudovirus-based neutralization assay is a reliable surrogate platform. In addition, it confirmed the functional accuracy of the epitope mapping strategy, showed the protective efficacy against a virulent RABV challenge in dogs, and demonstrated the broad neutralization spectrum of the SYN023 antibody cocktail against both RABV and a phylogenetically diverse panel of non-RABV lyssaviruses.
- 3 September 2026
- Published by MDPI AG in Preprints.org
Open AccessSYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background: Lyssaviruses remain a global public health threat, requiring broad-spectrum, high-potency neutralizing antibodies as part of recommended human rabies post-exposure prophylaxis (PEP). A humanized monoclonal antibody cocktail, SYN023, is approved for PEP in China and is under global regulatory review. Its epitope mapping data are promising. However, the neutralization breadth across diverse lyssaviruses and the reliability of pseudovirus-based neutralization assays still require comprehensive validation to support worldwide regulatory approval and clinical use. Methods: First, the correlation between authentic lyssaviruses virus and pseudotyped viruses neutralization was established experimentally to verify the reliability of the pseudovirus-based neutralization assay. Second, epitope mapping was performed using a highly virulent rabies virus (RABV) variant (New York City strain: NYC) provided by the U.S. Department of Agriculture, followed by in vivo PEP efficacy studies in a standardized canine model to functionally validate the mapped epitopes. Third, the neutralizing activity of SYN023 was evaluated against a phylogenetically diverse panel of non-RABV lyssaviruses and directly benchmarked against clinically validated comparator monoclonal antibodies, thereby providing robust, quantitative empirical evidence supporting its broad-spectrum neutralization capability. Results: A strong positive correlation was observed between neutralization titers elicited by authentic lyssaviruses and pseudotyped viruses (Pearson R2 = 0.83, P < 0.0001), validating the pseudovirus-based assay as a robust surrogate for authentic virus neutralization. Specifically, SYN023 recognized and potently neutralized the epitope mapped on the prototypic NYC RABV strain. The in vivo PEP studies conducted in a standardized canine challenge model, using the NYC strain as the challenge virus, demonstrated high protective efficacy at SYN023 doses ranging from 0.1 to 0.5 mg/kg. Furthermore, SYN023 exhibited broad, potent, and reproducible neutralizing activity against a phylogenetically diverse panel of non-RABV lyssaviruses, including European bat lyssavirus 1 (EBLV1), European bat lyssavirus 2 (EBLV2), Australian bat lyssavirus (ABLV), Bokeloh bat lyssavirus (BBLV), Taiwan bat lyssavirus 1 (TWBLV1), Taiwan bat lyssavirus 2 (TWBLV2), Kotalahti bat lyssavirus (KBLV), Divača bat lyssavirus (DBLV), Gannoruwa bat lyssavirus (GBLV), Duvenhage virus (DUVV), Khujand virus (KHUV), Aravan virus (ARAV), Mokola virus (MOKV), Lagos bat virus (LBV) and Shimoni bat virus (SHIBV). Notably, SYN023 achieved robust neutralization of MOKV (EC50 = 14.74 µg/mL), whereas clinically referenced monoclonal antibodies—Rabishield, Ormutivimab and GR1801—exhibited no detectable neutralizing activity against MOKV even at concentrations up to 1,000 µg/mL. This pan-lyssavirus neutralizing capacity was attributable mechanistically to SYN023’s targeting of a highly conserved conformational epitope within the viral glycoprotein, which is structurally preserved across all major lyssavirus phylogroups. Conclusion: This study demonstrated that the pseudovirus-based neutralization assay is a reliable surrogate platform. In addition, it confirmed the functional accuracy of the epitope mapping strategy, showed the protective efficacy against a virulent RABV challenge in dogs, and demonstrated the broad neutralization spectrum of the SYN023 antibody cocktail against both RABV and a phylogenetically diverse panel of non-RABV lyssaviruses.
- Open Access
- 1 January 2026
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 8 (3) , 64-70
Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies — China, 2025
Introduction The rapid fluorescent focus inhibition test (RFFIT) is a cell-based virus neutralization assay and the gold standard for quantifying rabies virus neutralizing antibodies (RVNA) in serums. It is used to assess the biological efficacy of rabies vaccines and evaluate protective immunity in both humans and animals. Despite its broad application, RFFIT requires thorough validation to ensure reliability. Methods RFFIT was validated in this study using the third World Health Organization international standard for anti-rabies immunoglobulin (WHO-3 SRIG) and negative human sera. The validation followed the guidelines outlined by the Food and Drug Administration Guidance for Industry and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)Q2 (R1) guidelines and included the assessment of intra-assay and intermediate precision, dilutability, linearity, range, accuracy, specificity, robustness, and stability. Results The RFFIT method demonstrated good precision, with intra-assay and intermediate-precision geometric coefficient of variation (GCV) y=1.0091x − 0.1128 (R2=0.9948); 95.56% of the samples showed 70%–130% recovery. Specificity was verified using homologous and heterologous antigen competition and a matrix with no significant cross-reactivity. The assay was robust to variations in cells, reagents, and time, with titer differences within ±30%. Stability of samples and reagents under freeze–thaw and different short-term storage conditions was confirmed. Conclusion The assay was successfully validated for quantifying RVNA content in serum samples.
- 1 January 2026
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 8 (3) , 64-70
Open AccessValidation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies — China, 2025
Introduction The rapid fluorescent focus inhibition test (RFFIT) is a cell-based virus neutralization assay and the gold standard for quantifying rabies virus neutralizing antibodies (RVNA) in serums. It is used to assess the biological efficacy of rabies vaccines and evaluate protective immunity in both humans and animals. Despite its broad application, RFFIT requires thorough validation to ensure reliability. Methods RFFIT was validated in this study using the third World Health Organization international standard for anti-rabies immunoglobulin (WHO-3 SRIG) and negative human sera. The validation followed the guidelines outlined by the Food and Drug Administration Guidance for Industry and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)Q2 (R1) guidelines and included the assessment of intra-assay and intermediate precision, dilutability, linearity, range, accuracy, specificity, robustness, and stability. Results The RFFIT method demonstrated good precision, with intra-assay and intermediate-precision geometric coefficient of variation (GCV) y=1.0091x − 0.1128 (R2=0.9948); 95.56% of the samples showed 70%–130% recovery. Specificity was verified using homologous and heterologous antigen competition and a matrix with no significant cross-reactivity. The assay was robust to variations in cells, reagents, and time, with titer differences within ±30%. Stability of samples and reagents under freeze–thaw and different short-term storage conditions was confirmed. Conclusion The assay was successfully validated for quantifying RVNA content in serum samples.
- Open Access
- 1 January 2025
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 7 (39) , 1241-1245
Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model — China, 2025
What is already known about this topic? Rabies is a fatal, but preventable, viral disease. Post-exposure prophylaxis (PEP), which includes the administration of passive immune preparations, is critical after exposure to the rabies virus, particularly in high-risk cases. The delayed or missed application of passive immunizing agents may increase the risk of infection. What is added by this report? SYN023, a novel anti-rabies monoclonal antibody cocktail, can effectively reverse the course of rabies infection, even at a late stage of the disease. In a mouse model infected with the rabies virus strain SC16, multiple high-dose injections of SYN023 administered 5 days post-inoculation rescued 69% of the animals. What are the implications for public health practice? These findings suggest that SYN023 could serve as a promising therapeutic agent for rabies PEP, particularly in cases in which treatment initiation is delayed. This study provides a scientific basis for future clinical trials aimed at improving rabies treatment protocols.
- 1 January 2025
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 7 (39) , 1241-1245
Open AccessEfficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model — China, 2025
What is already known about this topic? Rabies is a fatal, but preventable, viral disease. Post-exposure prophylaxis (PEP), which includes the administration of passive immune preparations, is critical after exposure to the rabies virus, particularly in high-risk cases. The delayed or missed application of passive immunizing agents may increase the risk of infection. What is added by this report? SYN023, a novel anti-rabies monoclonal antibody cocktail, can effectively reverse the course of rabies infection, even at a late stage of the disease. In a mouse model infected with the rabies virus strain SC16, multiple high-dose injections of SYN023 administered 5 days post-inoculation rescued 69% of the animals. What are the implications for public health practice? These findings suggest that SYN023 could serve as a promising therapeutic agent for rabies PEP, particularly in cases in which treatment initiation is delayed. This study provides a scientific basis for future clinical trials aimed at improving rabies treatment protocols.
- Open Access
- 28 July 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2382499
Development of mRNA rabies vaccines
Rabies, primarily transmitted to humans by dogs (accounting for 99% of cases). Once rabies occurs, its mortality rate is approximately 100%. Post-exposure prophylaxis (PEP) is critical for preventing the onset of rabies after exposure to rabid animals, and vaccination is a pivotal element of PEP. However, high costs and complex immunization protocols have led to poor adherence to rabies vaccinations. Consequently, there is an urgent need to develop new rabies vaccines that are safe, highly immunogenic, and cost-effective to improve compliance and effectively prevent rabies. In recent years, mRNA vaccines have made significant progress in the structural modification and optimization of delivery systems. Various mRNA vaccines are currently undergoing clinical trials, positioning them as viable alternatives to the traditional rabies vaccines. In this article, we discuss a novel mRNA rabies vaccine currently undergoing clinical and preclinical testing, and evaluate its potential to replace existing vaccines.
- 28 July 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2382499
Open AccessDevelopment of mRNA rabies vaccines
Rabies, primarily transmitted to humans by dogs (accounting for 99% of cases). Once rabies occurs, its mortality rate is approximately 100%. Post-exposure prophylaxis (PEP) is critical for preventing the onset of rabies after exposure to rabid animals, and vaccination is a pivotal element of PEP. However, high costs and complex immunization protocols have led to poor adherence to rabies vaccinations. Consequently, there is an urgent need to develop new rabies vaccines that are safe, highly immunogenic, and cost-effective to improve compliance and effectively prevent rabies. In recent years, mRNA vaccines have made significant progress in the structural modification and optimization of delivery systems. Various mRNA vaccines are currently undergoing clinical trials, positioning them as viable alternatives to the traditional rabies vaccines. In this article, we discuss a novel mRNA rabies vaccine currently undergoing clinical and preclinical testing, and evaluate its potential to replace existing vaccines.
- Open Access
- 22 February 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (4)
Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19
The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst public health crisis in a century. However, knowledge about the dynamics of antibody responses in patients with COVID-19 is still poorly understood. In this study, we performed a serological study with serum specimens collected at the acute and the convalescent phases from 104 patients with severe COVID-19 who were part of the first wave of COVID-19 cases in Wuhan, China. Our findings revealed that neutralizing antibodies to SARS-CoV-2 are persistent for at least 6 months in patients with severe COVID-19, despite that IgG levels against the receptor binding domain (RBD) and nucleocapsid protein (N) IgG declined from the acute to the convalescent phase. Moreover, we demonstrate that the level of RBD-IgG is capable of correlating with SARS-CoV-2–neutralizing activities in COVID-19 serum. In summary, our findings identify the magnitude, functionality, and longevity of antibody responses in patients with COVID-19, which sheds light on the humoral immune response to COVID-19 and would be beneficial for developing vaccines.
- 22 February 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (4)
Open AccessEffective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19
The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst public health crisis in a century. However, knowledge about the dynamics of antibody responses in patients with COVID-19 is still poorly understood. In this study, we performed a serological study with serum specimens collected at the acute and the convalescent phases from 104 patients with severe COVID-19 who were part of the first wave of COVID-19 cases in Wuhan, China. Our findings revealed that neutralizing antibodies to SARS-CoV-2 are persistent for at least 6 months in patients with severe COVID-19, despite that IgG levels against the receptor binding domain (RBD) and nucleocapsid protein (N) IgG declined from the acute to the convalescent phase. Moreover, we demonstrate that the level of RBD-IgG is capable of correlating with SARS-CoV-2–neutralizing activities in COVID-19 serum. In summary, our findings identify the magnitude, functionality, and longevity of antibody responses in patients with COVID-19, which sheds light on the humoral immune response to COVID-19 and would be beneficial for developing vaccines.